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Abstract: Despite significant advances in treatment strategies over the past decade, selective treat-
ment of breast cancer with limited side-effects still remains a great challenge. The cytochrome P450
(CYP) family of enzymes contribute to cancer cell proliferation, cell signaling and drug metabolism
with implications for treatment outcomes. A clearer understanding of CYP expression is important
in the pathogenesis of breast cancer as several isoforms play critical roles in metabolising steroid
hormones and xenobiotics that contribute to the genesis of breast cancer. The purpose of this review
is to provide an update on how the presence of CYPs impacts on standard of care (SoC) drugs used
to treat breast cancer as well as discuss opportunities to exploit CYP expression for therapeutic
intervention. Finally, we provide our thoughts on future work in CYP research with the aim of
supporting ongoing efforts to develop drugs with improved therapeutic index for patient benefit.
Keywords: Cytochrome P450; CYP1A1; CYP1B1; CYP2W1; breast cancer; prodrug; bioprecursor;
duocarmycin; phortress; AQ4N
1. Introduction
As our understanding of cancer improves, it has become increasingly evident that
targeted and patient-specific treatment strategies are essential for effective treatment. A one-
size-fits-all approach has multiple flaws in the face of a wide range of cancer subtypes,
with each patient harbouring specific genetic alterations and metabolic profiles. Immuno-
histochemical studies have classified breast cancer into four broad subtypes: oestrogen
receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth
factor receptor 2-positive (HER2+) and triple negative [1]. Patients harbouring tumours
that do not express any ER, PR or HER2 receptors are classified as triple negative breast
cancers (TNBC) [2]. Around 80% of the breast tumours are positive for the hormone recep-
tors wherein binding of the requisite chemical messenger to their receptor causes changes
in the cancer cell resulting in proliferation [3]. Although these receptors can be targeted
by drugs that disrupt the signalling process, hormonal therapies are still associated with
undesirable side effects including bone weakness and temporary or permanent menopausal
symptoms [4].
TNBC is the least common of all subtypes, disproportionately affecting pre-menopausal
African American women [5] and has been associated with poor clinical outcome. Treat-
ment relies heavily on chemotherapy as endocrine and targeted (e.g., trastuzumab-based)
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therapies are of no benefit in this disease [6]. As a consequence, the number of drug
combinations that can be used are limited thereby increasing the risk of developing drug
resistance [7]. Furthermore, there is far less understanding of how to treat TNBC compared
to receptor-positive cases as there are currently no known biomarkers to classify TNBCs ac-
cording to response. Further research is required to unravel the underlying causes of TNBC,
with deficiencies in underlying DNA repair mechanisms often being implicated [8–10].
2. Cytochrome P450 Function
The cytochrome P450 (CYP) superfamily of enzymes consist of a group of 57 human
isoforms that have the capacity to oxidise a vast variety of endogenous and xenobiotic
compounds [11]. In mammals, these enzymes are primarily involved in the metabolism of
drugs and fat-soluble vitamins, conversion of polyunsaturated fatty acids to biologically
active compounds and in the synthesis of steroid hormones. Apart from the capacity to
detoxify and inactivate many clinically used drugs, CYPs are also involved in conversion
of prodrugs into cytotoxic metabolites [12]. The ability of these enzymes to metabolise
both procarcinogens and anticancer drugs makes their study interesting in terms of cancer
aetiology and therapy. Differential endogenous expression of certain CYP genes in tumour
vs. normal tissue provides an opportunity for selective targeting with small molecules
designed to capitalise on CYP catalysis [13,14].
3. CYPs in Breast Cancer
A clearer understanding of CYP expression is important in the pathogenesis of breast
cancer as several isoforms play critical roles in metabolising steroid hormones. CYPs are
also essential for the conversion of environmental chemicals such as polycyclic aromatic
hydrocarbons (PAHs) to carcinogenic metabolites that contribute to the genesis of breast
cancer [15]. Critically, certain drugs used to treat advanced stages of breast cancer such as
paclitaxel display little or no cytotoxic activity after metabolism by CYP2C8 and CYP3A4
(Figure 1) [16,17]. Figure 2 outlines drugs used clinically to treat various stages of breast
cancer and which either benefit or suffer from intratumoural CYP expression [6,18].
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as a prognosis marker [20]. Some of these CYPs have been extensively studied on account
of their multifactorial roles in breast cancer aetiology and treatment. The purpose of this
review is to provide an update on how the presence of CYPs impacts on standard of care
(SoC) drugs used to treat breast cancer as well as discuss opportunities to exploit CYP
regulation and/or function for therapeutic intervention.
3.1. CYP1A1/A2
Expression of CYP1A1 is induced through the binding of substrates to the cytosolic
aryl hydrocarbon receptor (AhR) [21]. Elevated CYP1A1 mRNA expression has been de-
tected to varying degrees in many breast cancer subtypes which supports its potential as a
drug target in breast cancer treatment [22]. Expression of CYP1A1 has been found to be
high in breast tumour cells with a positive correlation to tumour grade and menopausal
status in newly diagnosed patients with adenocarcinoma of the breast [23]. Additionally, it
has been found to be overexpressed in breast cancers that are resistant to anti-oestrogen
treatment [24]. Knockdown of CYP1A1 has been shown to impair proliferation and sur-
vival in the breast cancer cell lines MCF-7 and MDA-MB-231 through activation of AMPK
signaling and inhibition of the phosphorylation of AKT, ERK and P70S6K [22]. There is
also some evidence that CYP1A1 is important for maintaining the integrity of breast cancer
stem cells (BCSCs), possibly by acting through β-catenin and PTEN/AKT signaling [25].
Increased basal level expression of CYP1A1 has also been observed in spheroids cultured
from MCF-7 breast cancer cells, compared to the monolayer, which was suppressed upon
co-culture with CD14+ cells in a macrophage-shaped environment [26]. This observation
reinforces the suppressive effect of inflammatory conditions on the expression of CYP1A1
in mammary epithelial cells which is an important factor that has to be considered while de-
signing immunomodulatory compounds and other chemotherapeutics that are bioactivated
by CYP1A1.
Several studies have shown that polymorphisms in drug-metabolising genes not
only pose as a risk factor for malignancy but also can serve as a predictive marker for
drug efficacy and targeted therapies [27,28]. In metastatic breast cancer, patients with the
CYP1A1*2C gene variant responded better to a treatment regimen involving docetaxel and
capecitabine compared to those with the homozygous wildtype (CYP1A1*1) genotype (AA)
who experienced a better efficacy with a combination of docetaxel with thiotepa [29]. In
early breast cancer, CYP1A2 rs762551 has been shown to be a potential predictive marker
for patients treated with aromatase inhibitors paving the way towards individualised
tailored assessment of therapy [30].
Prodrugs that are bioactivated by CYP1 enzymes can broadly be classified into
four groups of agents and include flavonoids, benzothiazoles, stilbenes and alkylating
agents [29]. Aminoflavone (NSC686288, Figure 3), a ligand of AhR, has been shown to
selectively induce apoptosis in MCF-7 breast cancer cells by activating the transcription
of CYP1A1 and CYP1B1 with functional activity confirmed using the ethoxyresorufin-
O-deethylase (EROD) activity assay both in vitro and in xenograft models [31]. Specific
activation of the lysine prodrug of aminoflavone (AFP464, NSC710464) and subsequent
CYP1 metabolic activation has been observed to be particularly effective in ER-positive
breast cancer cells compared with ER-negative counterparts. Epigenetic reactivation of ERα
expression treatment with the histone deacetylase (HDAC) inhibitor vorinostat has been
shown to sensitise resistant cells towards AFP464, through the transcriptional induction of
CYP1A1 [32]. Furthermore, AFP464 also inhibits the growth of tamoxifen-resistant breast
cancer cells exhibiting increased expression of α6-integrin linked to suppression of the
α6-integrin-Src-Akt signaling pathway [32]. Tamoxifen is a selective oestrogen receptor
modulator (SERM) used in the treatment of hormone-receptor-positive breast cancers.
AF464 entered a phase 1 clinical trial for advanced solid tumours where a maximally
tolerated dose (MTD) of 54 mg/m2 on day 1, 8 and 15 of a 28-day cycle and dose-limiting
pulmonary toxicity was observed [33]. Another prodrug, phortress, with selectivity to
ER-positive cells, has also been shown to be an AhR ligand, effectively inducing CYP1A1
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via the induction of the metabolite 5F203 to generate a number of metabolites including
a presumed nitrenium ion intermediate capable of causing DNA damage (Figure 3) [34].
More recently, CYP2W1 has also been shown to contribute to the bioactivation of 5F203 [35].
In a phase 1 study, no MTD was determined for phortress while pulmonary and liver
toxicities were observed [36]. The 50 patients that received phortress had advanced disease
including bowel, lung, oesophageal and stomach cancer, and the study concluded that
a “lack of efficacy” was observed, with no further clinical studies conducted. However,
in preclinical studies, phortress was first and foremost being progressed as a prodrug
with potential in ovarian and breast cancer but none of the 50 patients in the phase I trial
harboured these cancers, meaning the true efficacy remains unknown [34,37]. Despite the
discontinued clinical studies of AFP464 and phortress, AhR remains an interesting target
for 5F 203 [38] and several promising preclinical strategies have been discussed in a recent
review by McCluskey and co-workers and hence we refer to this for acquiring further
knowledge [32].
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Bioprecursor and prodrug approaches that rely on tumour-expressed CYP1A1 and
not AhR induc on for bioactivation includes our own work f cused on reenginee ed
duocarmycin molecules [39]. Duocarmycins are a class of exquisit ly potent naturally
occurr ng anti-tumour antibi tics that covalently bind the N3-p sition of adenine in the
min r roove of DNA, su seque tly resulting in ce l death [40]. The clinical u e of these
compounds as anticancer agents is limited du to lack of tumour s lectivity [41], however
deactivation of the pharmacophore offers an opportunity to s lectively target the oxidative
c pacity of CYP enzymes overexpressed in tumour tissue to r store the cell-killing ability
of these compounds [42,43]. The xenograft proof-of-concept studies have been successful
Biomedicines 2021, 9, 290 6 of 22
in bladder [44] and colorectal cancer [45] while preliminary data suggest the approach can
be translated to breast cancer as well [39]. Patterson and co-workers have also shown that
CYP1A1, as one of several CYPs, contributes in the conversion of the hypoxia-activated
prodrug AQ4N to the topoisomerase II inhibitor AQ4 (Figure 2D), which has shown
promise in a phase I trial that included six breast cancer patients [46,47]. Finally, CYP1A2
has been shown to contribute to bioactivation of the prodrug Tegafur to 5-FU [48], which
is frequently used as a part of postoperative combination treatment that include tegafur–
uracil (UFT) and tegafur–gimeracil–oteracil potassium (TS-1).
Another class of agent, the phenyl 4-(2-oxo-3-alkylimidazolidin-1-yl) benzenesulfonates
(PAIB-SOs), has recently been reported as CYP1A1-targeting prodrugs of anti-microtubule-
binding cytotoxins. The PAIB-SOs have been shown to display potent cytotoxic activity in
both CYP1A1-expressing hormone-dependent and chemo-resistant breast cancers cells both
in vitro and in vivo via N-dealkylation and prodrug activation (Figure 3) [49].
3.2. CYP1B1
Extrahepatic enzyme CYP1B1 has approximately 40% homology with CYP1A1 or
CYP1A2 and plays a vital role in the treatment of receptor-positive breast cancers due to its
ability to metabolise steroid hormones [12,50]. Expression of CYP1B1 is induced through
the AhR receptor by ligands such as polycyclic hydrocarbons and dioxins akin to CYP1As
and is mainly observed in tissues dependent on hormones such as mammary gland, ovary
and uterus. CYP1B1 is the most frequently expressed gene in breast cancer among the
CYP1 family members [51]. However, there have been conflicting reports regarding the
expression of CYP1B1 in tumours vs. the adjacent non tumour mammary gland tissues [20].
Although one reason for this disparity could be the increased sensitivity of transcript
detection compared to protein, the lower expression of CYP1B1 in cancerous tissue relative
to adjacent could also be attributed to the possible downregulation of the gene by the AhR
repressor in the tumour or by methylation of the promoter region, resulting in epigenetic
silencing [52]. Nonetheless, expression of CYP1B1 in hormone-mediated malignancies is
acknowledged to be important in the regulation of progression, metabolism, treatment
and resistance of breast tumours [53]. Along with inactivating clinically relevant anticancer
agents such as docetaxel and tamoxifen, CYP1B1 has also been shown to metabolise ta-
moxifen, 17 β-estradiol and bioactivate the natural product resveratrol to piceatannol, a
metabolite with antiproliferative activity [54]. Single nucleotide polymorphisms (SNPs)
have been found in the CYP1B1 gene, which accounts for the variation of drug efficacy
and toxicity between individual patients. A recent study reported that the expression
of CYP1B1 and SNPs 142 C > G, 4326 C > G were observed in TNBC patients with a
higher rate of metastasis and recurrence following administration with taxane, adriamycin
and cyclophosphamide (TAC) chemotherapeutic regimen [52]. Moreover, a higher expres-
sion of CYP1B1 was observed to be associated with increased drug resistance in breast
cancer cells corroborating its role as a predictor of drug resistance and a prognostic indi-
cator of treatment [55]. An overexpression of CYP1B1 and AhR has also been observed
in inflammatory breast cancer (IBC) which correlated significantly with tumour grade,
lymphovascular invasion, metastatic lymph nodes and the expression of Ki67 indicating
cell proliferation [56]. Inhibiting the expression of AhR using CRISPR-Cas9 resulted in the
decreased expression of CYP1B1, Wnt5a/b, and β-catenin in the IBC cell line SUM 149 [56].
Flow cytometry analysis also revealed that the subset of cells expressing a CSC pheno-
type (CD44+ CD24-/low) was positively correlated with the expression of AhR/CYP1B1,
Wnt5a/b and β-catenin in the carcinoma tissues of IBC patients. This reinstated the role of
AhR signaling in maintaining BCSCs subpopulations [25,56,57]. Whilst this study did not
provide a clear understanding of the potential role of other AhR-induced CYP1 isoforms
in breast CSCs, it partially substantiates the involvement of the receptor in regulating the
stem cell compartment within the tumour microenvironment.
Biomedicines 2021, 9, 290 7 of 22
3.3. CYP2A6/ CYP2A7
CYP2A6 is primarily involved in the metabolism of nicotine and hence is associated
with tobacco-related disorders including lung cancer. It is also one of the multiple CYPs in-
volved in the metabolism of tamoxifen (Figure 2A). In a study by Bieche et al., CYP2A6 was
identified as one among seven genes coding for major xenobiotic-metabolising enzymes in-
volved in breast tumourigenesis and which displayed a higher expression in ER-α-positive
breast tumours compared with ER-α-negative tumours and normal mammary tissues [58].
A 25% upregulation in CYP2A6 expression has been observed among ER-α-positive post-
menopausal breast cancer patients, which is contradictory to a study conducted by Iscan
and colleagues that failed to detect any mRNA expression of CYP2A6 in healthy or cancer-
ous breast tissues [15]. A possible explanation for these contradictory results may be due to
the fact that the latter study was conducted only in infiltrating ductal carcinoma subtype
of breast cancer without considering the hormone receptor status of the patients and also
had a limited sample size. Clearly, a more exact understanding of CYP2A6 expression
is significant for those patients who are being administered the prodrugs Tegafur and
cyclophosphamide (CPA) [14,59] that in part rely on CYP2A6 bioactivation (Figure 2B,C).
3.4. CYP2A13/2B6
In addition to CYP2A6, CYP2A13 also plays a significant role in smoking-induced
lung cancer due to its involvement in metabolising tobacco-specific nitrosamines [60].
In breast cancer, mRNA expression of CYP2B6 has been detected in both healthy and
cancerous breast tissues [15]. In pre-menopausal women with ER- and/or PR-positive
breast cancer, SNPs in CYP2B6 such as CYP2B6 rs4802101 (T/T) and CYP2B6 rs3211371
(T/C) have been associated with adverse prognosis [61]. The variability in the expression
and function of this isoform between individuals stem from its inducibility and frequent
polymorphism, respectively. CYP2B6 also plays major role in activating CPA in the liver by
oxidising the prodrug to a 4-hydroxycyclophosphamide (4-OH-CPA) which subsequently
produces a cytotoxic alkylating agent that damages DNA and eradicates tumour cells [14]
(Figure 2C). SNPs in CYB2B6 can have considerable impact on the expression, function
and pharmacokinetics of CPA. Variation in the alleles of CYP2B6 such as CYP2B6 *2, *4, *8
and *9 have been correlated with poor outcome while CYP2B6 *5 has been associated with
longer progression-free survival and higher dose delay incidence [62]. In metastatic breast
cancer patients receiving a combination of the chemotherapeutic drugs docetaxel and
thiotepa, it was observed that altered CYP2B6 genotypes such as AG genotype of rs2279343
and a CT/TT genotype of rs8192719 were beneficial and that the former was associated
with a decreased death risk (47%) and an overall survival increase of 6 months among
patients with liver metastasis [63]. Moreover, an in vitro study has shown 17 β-estradiol to
upregulate the expression of CYP2B6 exclusively in T-47D but not in MCF-7 breast cancer
cells by increasing the recruitment of ER-α and nuclear receptor coactivator 3 (NCoA3)
to the 5’ flanking region of the enzyme [64]. ER binding sites were also observed in an
upstream 5’ regulatory region of the CYP2B6 gene in several breast cancer cell lines.
3.5. CYP2C 8/9/18/19
Among all enzymes belonging to the CYP2C family, which contribute around 20% of
the total CYP transcript expression in human liver, CYP2C9 is the most abundant. CYP2C
enzymes are known to contribute to the activation of prodrugs such as the oxazaphospho-
rines [65], including CPA shown in Figure 2C. Both RNA and protein-level expression of
CYP2C9 and gene-level expression of CYP2C8 have been reported in a small cohort of
10 breast tumour samples [66]. No expression of CYP2C18 and CYP2C19 was observed
in these samples, which could be attributed to the downregulation of these CYPs by IL-6
cytokines in an autocrine manner, similar to observations in liver tissues [66]. Among
genetic variants of these genes, CYP2C9*2 polymorphism was found to be significantly
correlated with inferior therapeutic benefit from neoadjuvant chemotherapy [67]. Simi-
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larly, the efficacy of tamoxifen treatment in ER-positive breast cancer patients might be
influenced by an rs4917623 SNP in the CYP2C19 gene [68].
3.6. CYP2D6
Bioactivation of tamoxifen to a more potent, pharmacologically active and abundant
anti-oestrogenic metabolite “endoxifen” (4-hydroxy-N-desmethyltamoxifen) is a two-stage
process that involves N-desmethylation and 4-hydroxylation steps, which depends mainly
on the enzymatic activity of the rate-limiting enzyme CYP2D6 (Figure 2A). As a result, the
clinical efficacy of tamoxifen in each patient is dependent on the concentration of endoxifen
which further relies on the activity of the highly polymorphic enzyme CYP2D6 [69,70]. This
makes polymorphisms a key predictor of tamoxifen outcome in breast cancer patients [71].
Genetic variants of CYP2D6 can be classified based on the activity of the enzyme as exten-
sive, intermediate and poor metabolisers and these genotypes have a gene-dose effect on
the endoxifen concentrations in patients treated with tamoxifen [72]. In a study conducted
by Blancas et al. in 2018, a significantly lower disease-free survival was observed in a set of
87 patients taking adjuvant tamoxifen treatment with slow metabolisers compared to the
rapid counterparts [73]; we refer the reader to in-depth reviews [74,75] of how the variant
alleles of CYP2D6 can be used to predict the outcome in tamoxifen-treated breast cancer
patients. A recent study conducted with data from Swedish breast cancer cohorts demon-
strated a worse prognosis for both rapid and slow metabolisers (compared to normal),
which could be due to the occurrence of adverse effects of the treatment [76].
3.7. CYP2E1
Apart from being a phase 1 drug-metabolising enzyme, CYP2E1 is also associated
with several diseases like obesity, type-2 diabetes and liver diseases related to alcohol
consumption and cancer [77]. Increased expression of CYP2E1 in breast tumours correlated
with more serious and invasive lobular types of tumours [20]. Ectopic expression of the
enzyme in breast cancer cells has been shown to induce oxidative and ER stress, autophagy
while an inhibitory effect on metastasis was modulated by p53 as a possible upstream
regulator [77]. Furthermore, evidence also suggests that CYP2E1 regulates cellular energy
metabolism in a manner dependent on cell type and potentially on the clinical staging of
the disease and suggest a possible biomarker role [78]. The genetic polymorphic variant
CYP2E1 *6 Dra1 (D/C) has also been shown to correlate with higher risk of developing
breast cancer and warrants further investigation [79].
3.8. CYP2S1 and CYP2W1
Known as orphan CYPs, the biological functions of dioxin-inducible CYP2S1 and
CYP2W1 have not been elucidated [80]. Both isoforms appear to be differentially expressed
in cancerous tissues and their orphan status makes it interesting to explore their potential
as therapeutic targets. In a similar manner to CYP1 family members, AhR and ARNT
regulate the induction of CYP2S1 and the enzyme has been linked to metabolism of toxic
carcinogenic compounds via the peroxidase shunt [80,81]. The expression of CYP2S1 is
distributed among a variety of extrahepatic epithelial tissues that are susceptible to the
exposure of carcinogens and xenobiotics and also in several epithelial-derived cancers
including breast [19,80]. Contrarily, CYP2W1 transcripts are mainly restricted to foetal
and tumour tissues with minimal extrahepatic expression [82,83]. Apart from metabolis-
ing procarcinogens such as PAHs, CYP2W1 is also involved in the oxidation of indoline
substrates, lysophospholipids, free fatty acids and 17 β-estradiol [83]. Hlavac et al. in
2014 assessed transcript levels of 10 CYP enzymes in 68 post treatment tumours of breast
carcinoma patients and reported significantly higher intratumoural CYP2W1 in responders
of neoadjuvant chemotherapy compared to non- responders [84]. In breast cancer cell
lines MCF-7 and MDA-MB-231, constitutive expression of both CYP2S1 and CYP2W1were
detected, with greater abundance in MDA-MB-231 cells [82]. Moreover, treating the cells
with methoxy stilbenes or resveratrol increased the expression of CYP2S1 and CYP2W1 in
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MCF-7 but not in MDA-MB-231 cells at the genetic level. The benzothiazole 5F203 (and
analogue GW-610) was found to selectively induce the expression of CYP2S1 and CYP2W1
in isogenic breast cancer cells depleted for the isoforms [85]. Gene knockdown studies in
breast cancer cells identified the role of CYP2S1 in metabolically inactivating benzothiazoles
while induction of CYP1A1 remained crucial for their activation and anti-tumour proper-
ties [85]. In the molecular taxonomy of breast cancer international consortium (METABRIC)
cohort, high CYP2S1 mRNA was significantly associated with basal like breast cancers
compared to CYP2W1 which was predominantly expressed in luminal A tumours (SM and
RA unpublished data).
3.9. CYP3A4/A5
CYP3A4 is abundantly expressed and plays major role in metabolising 60% of the
marketed drugs including chemotherapy used to treat breast cancer patients such as CPA,
docetaxel, paclitaxel, etoposide, irinotecan, imatinib, lapatinib, trastuzumab emtansine and
tamoxifen [18,86]. CYP3A5 is commonly expressed in HER-2-positive breast cancers [84]
and is reported to be involved in the bioactivation of lapatinib [87]. Lapatinib, used in
the treatment of HER-2-positive metastatic breast cancer is metabolised by CYP3A4/5
in the liver. The metabolites have been known to cause idiosyncratic hepatocellular tox-
icity [88]. In addition, the nitroso metabolites of lapatinib can bind CYP3A4 forming a
metabolite–inhibitor complex that can inactivate CYP3A4 [89], however the clinical conse-
quences of the latter is unknown. Tumours negative for the expression of CYP3A4 have
been shown to have a better response rate to the antineoplastic drug docetaxel than those
expressing the enzyme [12]. Furthermore, higher expression of CYP3A4 has been shown
to be related to tumour progression in ER+ breast cancer cells, in part via the synthesis of
epoxyeicosatrienoic acids [90]. In 2001, Schmidt and colleagues identified the presence of
CYP3A4 in breast cancer microsomes which aided the metabolism and activation of the
CPA prodrug analogue ifosfamide [91]. DMI—a component of the trastuzumab–DMI con-
jugate used in the treatment of high-risk early stage and metastatic HER-2-positive breast
cancer [92], is metabolised by CYP3A4 and to a lesser extent by CYP3A5. Administering
trastuzumab–DMI with other agents that can act as CYP3A4 inhibitors (e.g., atazanavir,
clarithromycin, ketoconazole and indinavir) should be avoided to minimise potential
drug-related toxicity.
In postmenopausal tamoxifen-treated breast cancer patients, a genetic polymorphism in
CYP3A5 (CYP3A5*3) was found to be correlated with a positive response [93]. This finding is
contrary to that of Spitman et al. who suggested that there is no added benefit of CYP3A
genotype additionally to CYP2D6 variants on tamoxifen metabolism [94]. As the authors
claim, this discrepancy could possibly be due to the use of CYP3A4/5 inhibitors during
the latter study, which were not properly evaluated owing to the minimal data availability.
However, the mechanisms leading to tamoxifen resistance are less likely to be caused by a
single gene polymorphism since the metabolism of the drug is complex involving several
CYP enzymes.
3.10. CYP4Z1/Z2P
Orphan cytochrome CYP4Z1 is also known as a breast cancer-associated cytochrome
due to its putative role in breast cancer through the formation of a signaling molecule
20-hydroxyeicosatetraenoic acid (20-HETE) [95]. CYP4Z1 and its transcribed pseudogene
CYP4Z2P (96% identity) were initially cloned from SKBr3 breast cancer cells. Both these
enzymes are overexpressed in breast cancer, with CYP4Z2P having a similar expression
pattern to CYP4Z1 but at a generally lower level which is likely due to the degraded non-
functional protein product [96]. Expression of these enzymes is restricted to the mammary
glands while they have been shown to be overexpressed in breast carcinoma tissues, which
correlated with increasing tumour grade and poor prognosis [97]. Stable expression of
CYP4Z1 in breast cancer cells has been shown to enhance angiogenesis and tumour growth
in vivo by activating PI3K/Akt and ERK1/2 signaling pathways [97]. Intriguingly, in the
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breast cancer line MCF-7, CYP4Z1 was detected on the outside of the plasma membrane;
however, no isotype-matched antibodies were included as negative controls and so the
results must be treated with caution [98]. The study also detected autoantibodies against
the enzyme in the sera of patients with breast cancer in comparison to the control samples
suggesting a prospective role as a tumour-associated antigen [98]. The miRNA-mediated
competing endogenous RNA network (ceRNET) between CYP4Z1 and CYP4Z2P has been
suggested to inhibit apoptosis in breast tumours by serving as a sub-ceRNET to TERT and
also promotes angiogenesis and CDK3 expression [99].
3.11. CYP17A1 and CYP19A1
Endocrine therapy includes the use of SERMs such as tamoxifen and raloxifene and
the aromatase inhibitors: anastrozole, letrozole and examestane. The latter target CYP
aromatase (CYP19A1, oestrogen synthase) by intervening in the synthesis of aromatic C18
oestrogens (oestrone and oestradiol) from C19 androgens (androstenedione and testos-
terone). Mechanistic insights into CYP19A1 function, polymorphism and implication have
recently been reported and we refer to a recent review for further reading [100].
Although the steroidogenic biosynthetic pathway is complex and multifactorial, it
does offer targets for therapeutic intervention [101]. In men, CYP17A1 is a successful target
for abiraterone treatment of patients diagnosed with castration-resistant prostate cancer.
Abiraterone has also been explored in the treatment of patients with ER+ metastatic breast
cancer, as a single agent or in combination with exemestane but with no improvement in
progression-free survival [102]. Nonetheless, it is possible that a CYP17A1-targeting agent
such as abiraterone could be used with benefit in a subset of TNBC patients harbouring
tumours no longer responsive to standard treatment [103].
3.12. CYP24
The mitochondrial enzyme CYP24A1 (24-hydroxylase) manifests its key role in inac-
tivating 1 α, 25-dihydroxyvitamin D3 (1,25-(OH)2D3), the biologically active form of the
secosteroid hormone vitamin D and is a candidate oncogene [104]. 1,25-(OH)2D3 binds
to the vitamin D receptor (VDR) which is a ligand-activated nuclear receptor, which acti-
vates a network of genes that regulate calcium homeostasis, cell growth, differentiation
and functional activities of different cell types [105]. Elevated expression of CYP24A1, an
immediate target gene of VDR, has been observed in breast cancer cells with aberrant
amplification of the chromosomal loci encoding the gene [106,107]. In the absence of ligand,
the basal mRNA expression of CYP24A1 correlated inversely with VDR protein levels
in several breast cancer cell lines and the unliganded VDR exerts a repressive action on
CYP24A1 [108]. Knockdown of CYP24A1 using shRNA in mammary tumour lines resulted
in the suppression of the metabolism of vitamin D and abrogated tumour growth in vivo,
supporting the hypothesis that deficiency of vitamin D could be related to breast cancer
incidence [109]. There are several inhibitors for CYP24A1 including the naturally occurring
soy-derived isoflavane genestein which inhibits both CYP24A1 and CYP27B1 in a time-
and dose-dependent manner; the latter is an enzyme that also catalyses the conversion of
25-hydroxyvitamin D3 to 1,25-D3 [106,110].
3.13. CYP26A1/B1
CYP26 family generally functions by metabolising and clearing all-trans-retinoic
acid (ATRA) which is an active metabolite of vitamin A or retinol, involved in regulat-
ing cellular differentiation, proliferation, migration and apoptosis [111]. The major role
of the highly conserved members of this family CYP26A1, CYP26B1 and CYP26C1 ap-
pears to be in the conversion of retinoic acid (RA) to its metabolites, primarily 4-OH-RA.
Upregulation or overexpression of CYP26A1 triggers the signals for cell survival and anti-
apoptosis by inducing oncogenes and downregulating tumour suppressor genes along
with deregulating the cell cycle and DNA repair genes, perhaps indicating properties akin
to an oncogene [112,113]. CYP26A1 has been shown to be expressed at a constitutively
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higher level in breast adenocarcinomas which can be selectively inhibited, e.g., by use of
a RA metabolism blocking agent R116010, demonstrating an anti-tumour effect in ER+
mouse tumours [106]. Osanai et al. have demonstrated a strong cytoplasmic expression
of CYP26A1 in 42% of the primary breast carcinomas samples by immunohistochemistry
with significantly more intense staining observed in metastatic tumours. Breast cancer
cells overexpressing CYP26A1 displayed oncogenic properties, improved cell survival,
higher resistance to anoikis and enhanced tumorigenicity and metastatic potential [113]. RA
metabolism blocking agents (RAMBAs) together with ATRA have been shown to exhibit a
synergistic effect in regressing ER+ MCF-7 and MCF-7Ca xenografts in nude mice [114].
CYP26A1 also regulates the expression of the actin-bundling protein fascin by modulating
the levels of RA thereby affecting the malignant behaviour of CYP26A1 expressing breast
cancer cells [115].
3.14. CYP27A1
As a part of regulating intracellular cholesterol homeostasis, CYP27A1 (27-hydroxylase)
catalyses the hydroxylation of cholesterol to an oxysterol known as 27-hydroxycholesterol
(27HC), which is a SERM that can act as a partial agonist of the ER in breast cancers sub-
sequently stimulating growth and metastasis [116]. Differential expression of CYP27A1
has been observed in breast tumours correlating with the phenotype and prognosis of the
disease [117]. The role of CYP27A1 in metastasis is mediated by the action of circulating
metabolite 27HC on the function of myeloid cells located at distant metastatic niche in-
ducing a suppressed immune microenvironment [118,119]. Treatment with statins, drugs
used to manage hypercholesterolemia, have been shown to reduce the concentration of
27HC in the serum together with deregulation of the expression of this enzyme in breast
tumours [117]. Inhibition of CYP27A1 with aromatase inhibitors, such anastrozole and
fradrozole, has also proved to be beneficial in treating breast tumours dependent on ER
signaling [120].
4. CYP Isoform Expression in the Distinct Breast Cancer Subtypes and Implication in
Patient Survival
The impact of pharmacogenomics on cancer treatment together with our increasing
understanding of the role and presence of drug-metabolising enzymes supports the choice
of SoC drugs as well as in the discovery of new therapies. In breast cancer, a more routine
molecular profiling will allow the assessment of CYP expression patterns in support
of patient treatment selection, e.g., tamoxifen is mostly effective in patients expressing
CYP2D6 while in contrast paclitaxel is largely ineffective in patients expressing high levels
of CYP2C8 and CYP3A4. Design of targeted approaches exploiting the presence of selective
CYPs is key for tumour-selective therapy with minimised side effects. This is relevant in
neoadjuvant or adjuvant settings where conventional chemotherapeutic regimens are used
to reduce tumour bulk and/or growth and metastasis. However, certain factors should
be taken into consideration while utilising pharmacogenetics in personalising treatment.
Data from several studies suggests that multiple drug-metabolising genes are involved in
the metabolism of anticancer agents and signaling of oestrogen receptors. In this regard,
profiling of CYPs prior to treatment will support clinicians in predicting drug efficacy and
treatment outcomes. Moreover, there are possibilities of other accompanying medications
which can inhibit CYP enzymes thereby altering the drug metabolism and outcome [121].
Discontinuation of a therapy is another variable which is pivotal as a poor metaboliser may
benefit more from a continuous treatment than an extensive metaboliser who discontinues
the medication due to its side effects. Despite these shortcomings, tailoring patient-specific
CYP-directed therapeutic regimens in combination with routine chemotherapeutic agents
is a promising way to manage breast cancer. Interestingly, despite the vast number of
papers involving CYP expression in breast cancer, sparse information is available on CYP
isoform expression in the distinct breast cancer subtypes. Principal component analysis
using The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA)-BRCA mRNAseq
transcriptomic counts data (n = 935) with PAM50 subtype classifications (“Basal-like”,
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“Her2-enriched”, “Luminal A”, “Luminal B”, “Normal-like”) [122] revealed the CYP4
members CYP4X1 and CYP4Z1 to be highly expressed but not variable in a way that is
not associated with the PAM50 classifications (Figure 4 and Figure S1). CYP2A6, CYP2B6,
CYP2D6, CYP3A4 and CYP3A5 involved in drug metabolism of the breast cancer prodrugs
CPA, tegafur and tamoxifen (Figure 3) were expressed at various levels, but no significant
differences between the PAM50 groups were observed (data not shown). The divergence
of CYPs expression variance from the PAM50 classifications is concerning because it means
they will require separate analysis to form a distinct CYP profile. Currently we have only
a limited basis for the interpretation of a molecular CYP profile; however, we hope the
collection of these data will lead to enhanced therapeutic efficacy. Care must be taken
with interpretation of any molecular CYP profile in light of the transient nature of CYP
expression, their rapid response to any ongoing treatment will make rigorous collection of
metadata critical to objective assessment.
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CYP1 analysis of TCGA-BRCA RNAseq data revealed CYP1A2 expression to be very
low (max TPM = 1.3 with a median TPM = 0), while expression of CYP1A1 was high in a
subset of tumours (max TPM = 78.3 but median TPM = 0.04) and CYP1B1 was generally
more abundant (max TPM = 1611.7 and median TPM = 31.9). Both CYP1A1 and CYP1B1
showed significant (p < 0.0001) correlation with AhR expression (Spearman Rho = 0.14
and 0.41, respectively). Interestingly, the analysis indicates that CYP1B1 is likely regulated
by two different mechanisms because basal CYP1B1 expression is retained even in AhR-
low tumours, a feature that is not evident for CYP1A1 (Figure 5). CYP1B1 is implicated
in drug sensitivity so this observation is important for treatment-naïve patients. Future
studies are needed to evaluate transcript data from patients who have received AI or
chemotherapy treatment and it is possible much higher expression of CYPs induced by
AhR, CAR and PXR would be noticeable and an important factor to consider in patients
with relapsed tumours.
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Figure 5. Scatter plots showing the relationship between aryl hydrocarbon receptor (AHR) and CYP1A1 (A) or CYP1B1 (B)
gene expression, found both CYPs were significantly correlated with AHR in TCGA breast tumours (n = 1222).
The METABRIC analysis of CYP genes involved in the metabolism of anti-tumour
agents in breast cancer unravelled the association of some of these isoforms with patient
survival. In total, mRNA expression of 24 CYP genes was analysed using the ETABRIC
cohort, of hich expression of 9 genes ere significant and expression of 15 ere not
significant ith respect to patient survival.
Kaplan eier survival analysis shows that low CYP2A6 (p = 0.001), CYP2D6 (p = 0.024),
CYP2C8 (p = 0.013), CYP2E1 (p = 0.011), CYP26A1 (p < 0.0001) and high CYP2C9 (p = 0.034),
CYP2C18 (p = 0.003), CYP26B1 (p = 0.026) and CYP17A1 (p = 0.049) mRNA expression, in
the total patient cohort, was significantly associated with adverse brea t cancer-spe ific
survival (Figure 6). Overall, 434/1603 (27%) patients with low CYP2A6 expression died
compared to 70/353 (19%) patients with h gh expression. A similar trend was observed
for CYP2D6 expression, wherein 68/220 (30%) patients with low expression had worse
su vival compared to 437/1738 (25%) patien s with hig expression. A prop rtion of
305/1 25 (27%) patients with low CYP2C8 expression had adverse survi al compared to
200/834 (24%) with high expres ion. Si ilarly, low CYP2E1 (85/ 1
(87/251, 35%) expressing patients had adv r e survival compared to those with high
expression (420/1678, 25% and 4 8/1708, 24%, respectively).
An opposite trend was observed for CYP2C9 with igher expression resulti g in
adv rse survival, with 355/1297 (27%) events compared to 150/662 (22%) in patients
with low CYP2C9. Similarly, patients with high CYP2C18 (459/1698, 27%), CYP26B1
(134/475, 28%) and CYP17A1 (190/670, 28%) had worse survival compared to those with
low expression (i.e., 46/261, 18%, 371/1484, 25% and 315/1289, 24%, respectively).
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mRNA expression of CYP1A1 (p = 0.123), CYP1B1 (p = 0.109), CYP2A13 (p = 0.195),
CYP2C19 (p = 0.130), CYP2S1 (p = 0.279), CYP2W1 (p = 0.121), CYP3A4 (p= 0.194), CYP3A5
(p = 0.082), CYP4Z1 (p = 0.113), CYP4Z2P (p = 0.092), CYP19A1 (p = 0.054), CYP24A1
(p = 0.285), CYP26C1 (p = 0.055), CYP27A1 (p = 0.074) and CYP27B1 (p = 0.126), did not
show any significant association with survival (data not shown). Survival analysis could
not be conducted for CYP1A2 or CYP2B6 due to lack of gene expression information in the
METABRIC dataset.
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Figure 6. Kaplan–Meier survival analysis of CYP mRNA on breast cancer-specific survival. Survival curves showing
the impact of low (blue line) and high (red line) mRNA expression: (A) CYP2A6 (B) CYP2D6 (C) CYP2E1 (D) CYP2C8
(E) CYP2C9 (F) CYP2C18 (G) CYP17A1 (H) CYP26A1 (I) CYP26B1. Significance was determined using the log-rank test.
Significant p-values (<0.05) are indicated in bold.
Lower expression of CYP2A6 and CYP2D6, involved in the metabolism of tamoxifen,
tegafur and CPA [123,124] may result in inefficient metabolism/activation of these agents
which may affect survival of breast cancer patients as demonstrated in the current study.
Higher expression of CYP2C9 has been associated with cancer progression and aggres-
siveness with certain polymorphisms (CYP2C9*2 and CYP2C9*3) encoding enzymes with
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reduced activity [37]. Such polymorphic alleles may reduce responsiveness of patients to
agents such as tamoxifen and CPA [125].
5. Discussion and Future Directions
In spite of the significant advances in treatment strategies over the past decade, selec-
tive treatment of breast cancer with limited off-target effects still remains a great challenge.
CYP17A1 and CYP19A1 have been successfully pursued as targets for therapeutic interven-
tion and small molecule-based drugs such as abiraterone and the AIs anastrozole, letrozole
and exemastane are now established treatment options for prostate and breast cancer,
respectively. Although not discovered through rationalised drug discovery, tamoxifen,
tegafur and CPA are examples of CYP-activated prodrugs used to treat breast cancer. As
these prodrugs are not bioactivated in a tumour-selective manner, administration of these
agents is associated with side effects. Several prodrug strategies focused on targeting the
AhR and CYP1A1 and CYP1B1 expression have not yet translated into drug approval for
clinical use, but promising research in this area has been reported.
Considering the heterogeneity of breast tumours, it is well established that hypoxia
plays a key part in both chemo- and radio-resistance. Hypoxia occurs in approximately
40% of breast cancers and is more commonly seen in locally advanced primary breast
cancer [126]. Hypoxic regions have been found to occur in all breast cancer stages, from in
situ carcinomas to both lobular and ductal invasive cancers [127]. Studies have reported
that the mean pO2 in breast cancer ranges between 2.5 and 28mmHg (0.3–3.5% O2), with
a median value of 10 mmHg (1.3% O2), in comparison to 65 mmHg (8% O2) in normal
breast [128]. The presence of hypoxia in breast cancer decreases the effectiveness of hor-
monal therapy due to loss of ERα [129]. In patients with ductal carcinoma in situ (DCIS),
the presence of hypoxia or necrosis is associated with a shorter time to recurrence [130].
Furthermore, the presence of hypoxia in primary breast cancers has been associated with
hypoxia markers in their lymph node metastases, indicating that the hypoxia phenotype is
maintained even in metastatic lesions [131]. Accordingly, the presence of hypoxia can be
exploited for patient benefit via use of hypoxia-activated prodrug (HAP) therapy [132]. A
rationalised drug design and understanding of the bioreductive capacity of CYPs [133] in
solid tumours affected by hypoxic stress led to the development of AQ4N (Banoxantrone),
which has reached clinical evaluation [47] but not yet market approval. AQ4N has been
shown to be bioactivated under low oxygen tension by at least five CYPs (see Figure 2D)
to generate AQ4, a potent topoisomerase II poison. Given that patients harbouring breast
tumours with reduced oxygen tension have been linked to increased risk of mortality and
metastasis [134], there is a real opportunity for use of HAPs as an adjuvant in combination
with SoC treatment. Sadly, despite much promise, no HAP has yet been approved for clini-
cal use [135] but this field warrants further investigation in defining predictive biomarkers
for HAPs and overcoming the technical challenges of assaying them in clinical settings, as
argued elegantly in a recent review by Wilson and co-workers [136].
Regardless, of inhibitor or prodrug approach relying on intratumoural CYP expres-
sion for therapeutic intervention, it is important to advance the understanding of CYP
expression, function and regulation in the tumour microenvironment. This would include
careful investigations of 2D and 3D breast cancer models including co-culture systems,
spheroids, organoids, patient-derived xenograft models and clinical specimens. Analy-
sis of data from TGCA database did not reveal clear expression differences associated
with the PAM50 classification system as we have reported here, however more work is
required to fully understand regulation and expression in treatment-naïve and differently
treated patient cohorts. Furthermore, as alluded to in this review, it is also essential to take
into consideration the presence of CYP polymorphic variants and their function to better
understand how these impact on treatment outcomes.
In conclusion, acquiring in-depth knowledge on CYP expression and function is
important for improving current SoC treatment as well as guiding new and ongoing efforts
to develop drugs with improved therapeutic index for patient benefit.
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6. Methods
6.1. TCGA Analysis
TCGA-BRCA mRNAseq transcriptomic counts data were downloaded from the Na-
tional Cancer Institute (NCI) Genomic Data Commons dbGaP accession phs000178. The
results published here are based upon data generated by The Cancer Genome Atlas (TCGA)
managed by the NCI and National Human Genome Research Institute. Information
about TCGA can be found at http://cancergenome.nih.gov (accessed 18 January 2019).
PAM50 subtype classifications (“Basal-like”, “Her2-enriched”, “Luminal A”, “Luminal
B”, “Normal-like”) were taken from Ciriello et al. [122]. TCGA-BRCA mRNAseq data
were converted to transcripts per million (TPM) and log2 (TPM+1) values were used in
principal component analysis (PCA). Values for protein-coding CYP genes were extracted
and combined with those for the two essential reductases (P450 oxidoreductase: POR and
cytochrome b5: CYB5A). Gene expression was analysed in an unscaled PCA using prcomp
in R (version 3.6.1). Graphs were drawn by fviz_pca (version 1.0.3) in R. Plots display
contributions of the top 20 genes for clarity. All other graphs and statistical analyses were
generated in Prism (v.8.3.0; Graphpad).
6.2. METABRIC Analysis
Patient cohort
The molecular taxonomy of breast cancer international consortium (METABRIC)
dataset, containing sequencing data of 1980 primary breast cancer patients [137], was used
to assess the significance of CYP mRNA associations with patient survival. Information
about the METABRIC data set is published in Curtis et al., 2012. Patient tumours were
collected from 5 centres in the UK and Canada between 1977 and 2005. Median follow-up
was 141 months. Patients who were ER-positive and/or lymph node-negative did not
receive adjuvant chemotherapy, whereas all ER-negative and/or lymph node-positive
patients were administered adjuvant therapy. mRNA was isolated from primary patient
tumours in the METABRIC cohort and assayed using an Illumina HT-12 v3 platform [137].
6.3. Statistical Analysis
METABRIC cohort CYP data were stratified based on breast cancer-specific survival
(BCSS) using X-Tile software version 3.6.1 [138]. To assess the relationship between mRNA
expression and survival outcomes, survival curves were plotted using the Kaplan–Meier
method with significance determined using the Log-rank test. A p-value of <0.05 was
considered as statistically significant.
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